449 related articles for article (PubMed ID: 9700187)
1. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
Lunkes A; Mandel JL
Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
[TBL] [Abstract][Full Text] [Related]
2. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
[TBL] [Abstract][Full Text] [Related]
3. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions.
Lunkes A; Lindenberg KS; Ben-Haïem L; Weber C; Devys D; Landwehrmeyer GB; Mandel JL; Trottier Y
Mol Cell; 2002 Aug; 10(2):259-69. PubMed ID: 12191472
[TBL] [Abstract][Full Text] [Related]
4. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
[TBL] [Abstract][Full Text] [Related]
5. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
Hazeki N; Nakamura K; Goto J; Kanazawa I
Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
[TBL] [Abstract][Full Text] [Related]
6. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
7. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.
Kim M; Lee HS; LaForet G; McIntyre C; Martin EJ; Chang P; Kim TW; Williams M; Reddy PH; Tagle D; Boyce FM; Won L; Heller A; Aronin N; DiFiglia M
J Neurosci; 1999 Feb; 19(3):964-73. PubMed ID: 9920660
[TBL] [Abstract][Full Text] [Related]
8. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
Li SH; Li XJ
Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
[TBL] [Abstract][Full Text] [Related]
9. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
[TBL] [Abstract][Full Text] [Related]
10. Huntingtin fragments that aggregate go their separate ways.
DiFiglia M
Mol Cell; 2002 Aug; 10(2):224-5. PubMed ID: 12191468
[TBL] [Abstract][Full Text] [Related]
11. Huntingtin processing in pathogenesis of Huntington disease.
Qin ZH; Gu ZL
Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
[TBL] [Abstract][Full Text] [Related]
12. Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high-capacity adenoviral vectors expressing truncated and full-length huntingtin with polyglutamine expansion.
Huang B; Schiefer J; Sass C; Kosinski CM; Kochanek S
J Gene Med; 2008 Mar; 10(3):269-79. PubMed ID: 18067195
[TBL] [Abstract][Full Text] [Related]
13. Complex interplay between the length and composition of the huntingtin-derived peptides modulates the intracellular behavior of the N-terminal fragments of mutant huntingtin.
Milewski M; Gawliński P; Bąk D; Matysiak A; Bal J
Eur J Cell Biol; 2015 May; 94(5):179-89. PubMed ID: 25773959
[TBL] [Abstract][Full Text] [Related]
14. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.
Sugars KL; Brown R; Cook LJ; Swartz J; Rubinsztein DC
J Biol Chem; 2004 Feb; 279(6):4988-99. PubMed ID: 14627700
[TBL] [Abstract][Full Text] [Related]
15. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
[TBL] [Abstract][Full Text] [Related]
16. DMSO and glycerol reduce bacterial death induced by expression of truncated N-terminal huntingtin with expanded polyglutamine tracts.
Nagao Y; Ishiguro H; Nukina N
Biochim Biophys Acta; 2000 Oct; 1502(2):247-56. PubMed ID: 11040449
[TBL] [Abstract][Full Text] [Related]
17. Protein aggregation in Huntington's disease.
Hoffner G; Djian P
Biochimie; 2002 Apr; 84(4):273-8. PubMed ID: 12106904
[TBL] [Abstract][Full Text] [Related]
18. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
19. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
